对叠氮基苯乙二醛一水合物 | 1196151-49-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 对叠氮基苯乙二醛一水合物
• 英文名称: 4-Azidophenyl glyoxal hydrate
• 英文别名: 2-(4-azidophenyl)-2-oxoacetaldehyde;hydrate
• CAS: 1196151-49-1
• 化学式: C8H7N3O3
• 分子量: 193.16
• InChiKey: CBYYPIYKJZCKGK-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.19
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.5
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] DISULFIDE BIOCONJUGATION<br/>[FR] BIOCONJUGAISON DE DISULFURE
  申请人：UNIV CALIFORNIA

  公开号：WO2018201000A1

  公开（公告）日：2018-11-01

  Compounds and methods are provided for one-step functionalization of disulfide bonds in proteins.

  提供了一种步骤的方法和化合物，用于在蛋白质中对二硫键进行功能化。
• Site-directed coupling of proteins
  申请人：Vectron Therapeutics AG

  公开号：EP1557429A1

  公开（公告）日：2005-07-27

  The present invention relates to a method of modifying a polypeptide, which yields a modified polypeptide, suitable for site-specific coupling, for example, as a targeting ligand, as well as modified human EGF and fragments thereof, suitable for site-specific coupling.

  本发明涉及一种修饰多肽的方法，该方法可获得适合于位点特异性偶联的修饰多肽，例如作为靶向配体，以及适合于位点特异性偶联的修饰人EGF及其片段。
• Agents that modulate EPH receptor activity
  申请人：The Burnham Institute

  公开号：EP1852441A2

  公开（公告）日：2007-11-07

  Novel agents are described that bind to Eph receptors. Methods of using these agents to modulate the activity of Eph receptors, stimulate apoptosis, and deliver therapeutic agents are also described. Methods of screening for agents capable of selectively binding to Eph receptors are also described.

  描述了与 Eph 受体结合的新型制剂。还描述了使用这些制剂调节 Eph 受体的活性、刺激细胞凋亡和递送治疗药物的方法。还介绍了筛选能够选择性地与 Eph 受体结合的制剂的方法。
• Complement factor H-derived short consensus repeat-antibody constructs
  申请人：Medizinische Universität Innsbruck

  公开号：EP2208737A1

  公开（公告）日：2010-07-21

  The present invention relates to a complement activating construct comprising a complement factor H-derived short consensus repeat (fH-derived SCR) and a binding molecule which specifically recognizes a pathogen. More specifically, the fH-derived SCR is selected from the group consisting of SCR7, SCR9, SCR13, SCR18-20 and artificial SCR (aSCR). Furthermore, an in vivo method for screening complement-based approaches for the treatment of the prevention, treatment or amelioration of an infection with a pathogen or a pathological condition associated with an infection with a pathogen is described.

  本发明涉及一种补体激活构建物，该构建物由补体因子 H 衍生的短共识重复序列（fH-derived SCR）和特异性识别病原体的结合分子组成。更具体地说，fH-衍生SCR选自SCR7、SCR9、SCR13、SCR18-20和人工SCR（aSCR）组成的组。此外，还描述了一种体内方法，用于筛选基于补体的治疗方法，以预防、治疗或改善病原体感染或与病原体感染相关的病理状况。
• BONE DEFECT FILLER NOT ADSORBING BONE GROWTH FACTOR AND NOT INHIBITING THE ACTIVITY OF THE SAME
  申请人：The University of Tokyo

  公开号：EP2308518A1

  公开（公告）日：2011-04-13

  An object of the invention is to provide a bone filling material capable of promoting the bone regeneration effect of a growth factor such as platelet rich plasma (PRP). Inventors of the invention anticipated that the bone filling material adsorbs a growth factor like PRP, and the combined use of the bone filling material with PRP, the bone regeneration effect of PRP might be impaired. Further, the invention is basically related to the inhibition of this adsorbing effect of the bone filling material by using a capping agent. Since the adsorbing effect of the bone filling material is thus inhibited, PRP can exert the bone regeneration effect thereof in the case of using the bone filling material together with PRP.

  本发明的目的是提供一种能够促进富血小板血浆（PRP）等生长因子的骨再生效果的骨填充材料。 本发明的发明者预计，骨填充材料会吸附 PRP 等生长因子，而将骨填充材料与 PRP 结合使用，可能会损害 PRP 的骨再生效果。此外，本发明基本上与通过使用封盖剂抑制骨填充材料的这种吸附作用有关。由于骨填充材料的吸附作用因此受到抑制，在将骨填充材料与 PRP 一起使用的情况下，PRP 可发挥其骨再生作用。